Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") provides an update on the clinical development of its oral first-in-class pan-norovirus and pan-coronavirus dual protease inhibitor CDI-988 and its oral
Cocrystal Pharma, Inc. (NASDAQ:COCP) (Cocrystal or the Company) announces receipt of authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 2a human challenge
Cocrystal Pharma, Inc. (NASDAQ:COCP) (Cocrystal or the Company) announces that new data from its CC-42344 Phase 1 influenza A Study was presented today by Sam Lee, Ph.D., President and co-CEO, at the 7th Annual
Cocrystal Pharma, Inc. (NASDAQ:COCP) (Cocrystal or the Company) announces the acceptance of an oral presentation containing new data from the Company's CC-42344 Phase 1 influenza A study at the 7th Annual